Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma

Clinical trial NCT00422786 · COMPLETED

Trial details

NCT number: NCT00422786
Sponsor: Thallion Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Renal Cell

Start date: 2007-03-01
Primary completion: 2008-03-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.